Sanofi, OpenAI, Formation Bio announce AI drug development partnership

French pharmaceutical giant Sanofi will work with the tech powerhouse OpenAI and New York-based startup Formation Bio to develop AI-powered software in drug R&D, the three companies announced Tuesday.

The deal is the latest example of a tightening relationship between drugmakers and AI companies, and the second major deal that OpenAI has made in the biopharma industry, after announcing a collaboration arrangement with Moderna last month.

Details of the announcement were vague, though the companies stated they would “bring together data, software, and tuned models to develop custom, purpose-built solutions across the drug development lifecycle.” In particular, Sanofi will bring its proprietary data, OpenAI will provide its AI expertise and ability to fine-tune models, and Formation Bio will bring its engineering resources, the companies said. A Sanofi spokesperson added the trio will focus on customizing large language models designed for drug development.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks